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Introduction
COPD is a chronic debilitating disease with disabling
symptoms. Our ability to improve lung function pharmaco-
logically in patients with COPD is quite limited. Surgical
options (lung volume reduction surgery, lung transplanta-
tion) can produce substantial improvements in some
patients, but are associated with significant morbidity and
mortality, and are only indicated in a minority of patients. It
has recently become apparent that skeletal muscle dys-
function is common in patients with COPD, and may play
a role in reducing exercise tolerance. Therapeutic efforts
to improve skeletal muscle function could lead to consid-
erable benefits in such patients. The present review
focuses on the evidence for skeletal muscle dysfunction in
patients with COPD, as well as on potential mechanisms
of and therapies to combat this dysfunction.
Skeletal muscle dysfunction
Strength
Muscle strength is decreased in patients with COPD as
compared with age-matched control individuals [1–3].
Lower limb muscles are affected to a greater extent than
are upper limb muscles [1–3]. The preferential reduction
in lower limb strength may be due to a greater reduction in
activity of the lower limbs in these patients. On average,
quadriceps strength is decreased by 20–30% in patients
with moderate to severe COPD [2,3]. However, there is
considerable variability among patients, with some
patients having relatively normal values, whereas others
have a reduction in strength of more than 50%.
In one study [1], the cross-sectional area of the thigh was
measured using computed tomography scanning. In that
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study the reduction in strength was proportional to the
reduction in thigh area (ie the reduction in strength was
entirely due to muscle atrophy). A subgroup of patients
who had previously received steroids did have a greater
reduction in strength than in muscle mass. Further studies
are required to determine whether patients with particular
clinical characteristics will display a reduction in muscle
strength that is out of proportion to their reduction in
muscle mass. Quadriceps strength was significantly corre-
lated with the forced expiratory volume in 1 s (FEV1) [1];
the lower the FEV1, the weaker the quadriceps muscle.
Quadriceps strength also correlated with exercise capac-
ity, both peak exercise capacity [1,3] and 6-min walking
distance [3], independently of lung function. However,
correlation does not represent causation.
Endurance
Several studies [4–6] have compared limb muscle
endurance in patients with COPD and healthy control indi-
viduals. Measurement of endurance is particularly affected
by motivational factors, and variability in measurements
can be quite high. Two studies [4,5] examined quadriceps
endurance. One study found a significant reduction in
quadriceps endurance in patients with COPD [4],
whereas the other did not [5]. This finding may reflect het-
erogeneity in skeletal muscle function between patients
with COPD. However, the smaller number of patients eval-
uated in the negative study (six versus 17) may also be
important. Small reductions in endurance of upper limb
muscles (elbow flexors and adductor pollicis) have also
been demonstrated in patients with COPD [5,6].
Fatigability
When normal individuals exercise vigorously the exercising
muscle develops contractile fatigue. With contractile
fatigue, the force generated by the muscle for a given
neural input decreases. Patients with COPD become
breathless when they exercise, and may stop exercise
because of breathlessness before they stress the exercis-
ing musclesufficiently to develop fatigue.
We measured quadriceps twitch force (a measure of
fatigue) before and after high-intensity cycle exercise to
the limits of tolerance in a group of patients with moder-
ately severe COPD [7]. We found a significant reduction
in twitch force after exercise in 11 out of 19 patients.
Thus, the majority of patients displayed contractile fatigue
of the quadriceps muscle (the primary working muscle
during stationary cycling) despite their having a severely
reduced exercise capacity (the peak oxygen consumption
[VO2] averaged 51% of predicted). In a subsequent study
we measured potentiated quadriceps twitch force (a more
sensitive index of contractile fatigue [8]) in a group of
patients with COPD of varying severity. Potentiated twitch
force fell in 17 out of 21 patients after exercise [9]. Thus,
most patients with COPD will develop contractile fatigue
of the exercising muscle after exercise to the limits of toler-
ance. Patients with severe disease (FEV1 <40% of pre-
dicted) were as likely to develop exercise-induced
quadriceps fatigue (seven out of nine) as those with milder
disease (10 out of 12) [9].
Healthy elderly individuals also develop exercise-induced
quadriceps fatigue after cycle exercise to the limits of tol-
erance [10]. The degree of exercise-induced quadriceps
fatigue was not significantly different between the healthy
elderly and the patients with COPD, even though the
patients with COPD exercised at a significantly lower
workload. These results suggest that the quadriceps
muscle is more fatigable in patients with COPD than in
healthy elderly persons.
Muscle fiber type
In general, biopsies of the quadriceps muscle in patients
with COPD have shown a reduced proportion of type I
fibers and an increase in the proportion of type II fibers as
compared with normal individuals [11–15]. Type I fibers
are slow-twitch fibers, develop a relatively small tension,
have increased oxidative capacity, and are resistant to
fatigue. Type IIb fibers are fast-twitch fibers, develop high
tensions, depend primarily on anaerobic glycolytic metabo-
lism, and are highly susceptible to fatigue. Type IIa fibers
are intermediate in character. The increased proportion of
type II fibers was of type IIb in most studies, but an
increase in type IIa fibers with no change in type IIb fibers
has also been reported. This shift in fiber proportion should
help to preserve strength, but at the cost of increased fati-
gability and reduced muscle endurance. However, the rela-
tive proportion of fiber types had no independent effect on
exercise capacity [12,13]. In addition to the shift in fiber
type, there is a reduction in cross-sectional area of type I
and type IIa fibers (ie muscle atrophy is present) [11].
Muscle capillarity
Muscle capillarity is an important component of skeletal
muscle oxidative capacity. The number of capillaries/mm2
was significantly lower in patients with COPD than in
healthy control individuals [14]. The ratio of capillary to
fiber was also significantly lower in patients with COPD in
one study [14], but this ratio did not reach statistical sig-
nificance in another [11]. The ratio of capillary to fiber did
not improve following a physical training program [11].
Muscle metabolism
Several studies in which the quadriceps muscle was biop-
sied [16,17] showed a reduction in oxidative enzyme
capacity in patients with COPD as compared with control
individuals. Citrate synthase (an enzyme that is involved in
the citric acid cycle) and, to a lesser extent, 3-hydroxyacyl
coenzyme A dehydrogenase (an enzyme that is involved in
b-oxidation of fatty acids) are both significantly reduced in
patients with COPD. Citrate synthase activity significantlyRespiratory Research    Vol 2 No 4 Mador and Bozkanat
correlated with peak VO2, independently of lung function
[18]. In one study [16], phosphofructokinase (a glycolytic
enzyme that is involved in anaerobic metabolism) was sig-
nificantly increased in patients with COPD, but this finding
was not confirmed in a subsequent study [17].
Cytochrome oxidase (the terminal enzyme in the mitochon-
drial electron transport chain) activity was significantly
increased in patients with COPD and resting hypoxemia
[19]. It had been believed that all oxidative enzymes would
respond in a qualitatively similar fashion to deconditioning,
training, etc. However, these results suggest that different
oxidative enzymes may be regulated differently in patients
with COPD.
Cellular bioenergetics can also be measured in vivo in
humans by 31P magnetic resonance spectroscopy (MRS).
The ratio of intracellular phosphocreatine to inorganic
phosphate (Pi) is closely related to that of ATP to ADP,
and is believed to be a useful measure of mitochondrial
phosphorylation potential. Intracellular pH can also be
measured using 31P-MRS. Recovery times for phospho-
creatine after exercise have been used to assess mito-
chondrial density and function. A number of studies have
utilized this technology in patients with COPD. However,
in many of the studies patients were chronically hypoxic or
had chronic hypercapnic, hypoxemic respiratory failure.
The muscles usually studied are those in the forearm or
calf, because these are the easiest muscles to position
within the coil. More recently, technology has evolved that
permits assessment of the quadriceps muscles during and
after exercise. However, the ability to measure precisely
the same area of the muscle with no pollution of the signal
from adjacent muscles before, during, and after exercise is
probably not as good for the quadriceps muscle as it is for
the calf or forearm muscles. It should be remembered that
lower limb muscles are particularly susceptible to decon-
ditioning, and appear to be more impaired than upper limb
muscles in patients with COPD.
In one study of the quadriceps muscle in normoxic
patients with COPD [20], the Pi : phosphocreatine ratio
was higher and intracellular pH lower in patients with
COPD than in age-matched control individuals at the
same absolute work rate. Similarly, the half-time for phos-
phocreatine recovery was significantly longer in the
patients with COPD. These results provide further support
that oxidative metabolism in the exercising muscle is
impaired in patients with COPD. The increased Pi : phos-
phocreatine ratio and decreased intracellular pH during
exercise were observed in previous studies in the forearm
and calf muscles [21–25]. A prolonged half-time for phos-
phocreatine recovery was observed in some [22,24,25],
but not all previous studies [23].
Blood lactate levels start to increase at very low work
rates in patients with COPD [26,27]. Because blood flow
to the leg is within normal limits in patients with COPD
[27], the increase in lactate is due to an increase in net
lactate output across the leg, probably because of
increased lactate production within the exercising muscle.
Oxygen delivery to the exercising leg is also not impaired
in patients with COPD [27], suggesting that the increase
in lactate production is due to an intrinsic muscle abnor-
mality (reduced oxidative capacity) that results in early
activation of anaerobic glycolysis.
Mechanisms of skeletal muscle dysfunction
Disuse
Patients with COPD tend to reduce their level of physical
activity because exertion causes unpleasant sensations. A
vicious cycle can result, with reductions in physical activity
producing more deconditioning, and more impairment in
skeletal muscle function leading to more symptoms at
lower levels of work. Inactivity produces a number of struc-
tural and biochemical changes [28–30]. Muscle mass
decreases and type IIa fibers tend to convert to type IIb. A
reduction in the proportion of type I fibers with prolonged
inactivity has been reported [31]. Oxidative enzyme con-
centration, the number and density of mitochondria, and
the number of capillaries all decrease [28–30]. Reduc-
tions in oxidative capacity and muscle atrophy are
common in patients with COPD. Deconditioning is almost
certainly an important factor in the skeletal muscle dys-
function that is observed in patients with COPD.
Medications
Short courses of high-dose corticosteroids are used to
treat acute exacerbations in patients with COPD. Low-
dose oral corticosteroids have been used chronically to
treat some patients with COPD, although the efficacy of
this approach is hotly disputed. Steroid-induced myopathy
has been well described, and may be more common than
was initially appreciated. Histologically, both myopathic
changes and generalized fiber atrophy are seen [32]. In
one study [32], survival of patients with steroid-induced
myopathy was significantly lower than that in a matched
group of patients with COPD and a similar degree of
airflow obstruction. In a provocative study [33], the
average daily dose of steroids was measured for 6 months
in a group of patients with COPD or asthma. Only one
patient was receiving daily steroids. The other patients
received bursts of steroids for exacerbations of their
disease. The average daily dose of steroids was only
4.3 mg (range 1.4–21.3 mg). Eight out of 21 patients had
significant quadriceps weakness, as defined as a reduc-
tion in quadriceps force below the normal range. An
average daily dose of steroids that exceeded 4 mg/day
was more common in patients with quadriceps weakness
than in those without. The average daily dose of steroids
explained 51% of the variance in quadriceps force mea-
surements. The results of this study were interpreted as
indicating that bursts of steroids might cause peripheralmuscle weakness. An alternative explanation is that
patients with repetitive exacerbations are sicker, and
therefore weaker than those without exacerbations.
Hypoxia
Chronic hypoxia adversely affects skeletal muscles. With
prolonged exposure to high-altitude hypoxia, glycolytic
enzyme (which is active in anaerobic metabolism) activity
increases, whereas oxidative enzyme activity decreases
[34]. Hypoxia also increases oxidative stress, which can
adversely affect muscle performance [35]. In animals,
hypoxia leads to a reduction in muscle fiber diameter [36].
Muscle fiber cross-sectional area is decreased in moun-
tain climbers undergoing prolonged hypoxia (greater than
6 weeks) [37].
Hypercapnia
Short-term exposure to hypercapnia results in skeletal
muscle weakness, but no change in fatigability [38,39]. In
acute hypercapnic respiratory failure marked derange-
ments in energy metabolism are seen, with marked reduc-
tions in ATP and phosphocreatine concentrations [40,41].
Acute hypercapnia also contributes to intracellular acido-
sis in patients with acute respiratory failure [41]. The
effects of chronic hypercapnia need to be delineated.
Nutrition
Nutritional depletion is common in patients with COPD. A
commonly used definition of nutritional depletion is a body
weight less than 90% of ideal body weight. Using this def-
inition, 35% of patients entering a pulmonary rehabilitation
program were nutritionally depleted [42]. Body weight can
be divided into fat and fat-free mass. Patients can be nutri-
tionally depleted with a reduced fat-free mass, despite
having a body weight within normal limits (due to an
increased proportion of fat mass). Approximately 10% of
patients meet this criteria [42].
A prolonged period of under-nutrition results in a reduc-
tion in muscle strength and endurance [43–45]. Under-
nutrition results in a reduction in muscle mass and fiber
atrophy [43,46]. Type II fibers are affected to a greater
extent than are type I fibers [43,46]. Glycolytic and oxida-
tive enzyme activity are both reduced [46,47]. Muscle
bioenergetics may also be impaired; high ADP levels and
reduced phosphocreatine levels after contraction have
been reported in food-deprived animals [47,48].
Oxidative stress
Oxidative stress may also contribute to the skeletal muscle
dysfunction that is observed in patients with COPD.
Increased plasma concentrations of lipid peroxidation
products have been observed in patients with COPD
during acute exacerbations [49]. The main source of these
oxygen free radicals is mitochondria [50,51]. However,
another source is immune cells activated by inflammation.
Elevated tumor necrosis factor-a levels have been
observed in patients with COPD and weight loss [52,53].
Susceptibility of a tissue to free radicals depends largely
on the antioxidant status of the tissue [50]. The antioxidant
status of skeletal muscle may be impaired by disuse or
chronic hypoxia, or both.
Therapy
Exercise training
Deconditioning from disuse is believed to be a major con-
tributing factor in the skeletal muscle dysfunction that is
observed in patients with COPD. Therefore, exercise train-
ing in this setting should be helpful. In normal individuals,
an endurance training program produces a number of
morphologic and physiologic changes within the exercis-
ing muscle that increase its aerobic capacity [28]. These
changes include an increase in mitochondrial number,
increased muscle capillarization, and an increase in
muscle oxidative enzyme activity. After intense training the
proportion of type I fibers increases, whereas type IIb
fibers can transform to type IIa [54]. In order for an
endurance-training program to produce these results,
exercise must be above a critical minimum intensity (the
minimum intensity has not been precisely defined, but
exercise at 50–60% of maximal VO2 is clearly above it),
and must be of sufficient duration and frequency [55].
It was formerly believed that patients with COPD could
not perform exercise at a sufficient intensity (ie above the
critical minimum intensity) to produce physiologic adapta-
tions within the exercising muscle. In a previous study
[56], muscle oxidative enzyme activity did not change after
exercise training in a group of patients with COPD.
However, the patients exercised at a relatively low inten-
sity, even for patients with COPD. When patients with
COPD underwent a more intensive training regimen an
increase in oxidative enzyme activity was observed after
training, clearly showing that patients with COPD can
exercise sufficiently to undergo adaptations in the exercis-
ing muscle [57].
In a study that employed 31P-MRS in the quadriceps
muscle [20] an improvement in cellular bioenergetics was
observed after pulmonary rehabilitation. For the same
duration and intensity of submaximal exercise, the
Pi:phosphocreatine ratio decreased and intracellular pH
increased as compared with before rehabilitation. Simi-
larly, the half-time of phosphocreatine recovery decreased
after pulmonary rehabilitation. These improvements in
bioenergetic state are consistent with an improved mito-
chondrial oxidative capacity. Quadriceps endurance has
been assessed in patients with COPD by performing
repeated dynamic contractions until exhaustion at different
power outputs. After pulmonary rehabilitation endurance
time was significantly increased at all power outputs, indi-
cating that quadriceps endurance was improved after
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before and after pulmonary rehabilitation in 21 patients
with COPD [9]. Quadriceps contractile fatigue was
assessed by measurement of quadriceps twitch force
during supramaximal magnetic stimulation of the femoral
nerve before and after constant load cycle exercise. For
the same duration and intensity of exercise, the degree of
exercise-induced quadriceps fatigue was significantly
decreased after pulmonary rehabilitation. Thus, pulmonary
rehabilitation resulted in increased fatigue resistance in
the quadriceps muscle.
It is clear that exercise training can improve skeletal
muscle function in patients with COPD. Exercise training
(pulmonary rehabilitation) was shown to improve
endurance exercise capacity and quality of life in patients
with COPD [59,60]. Further studies are required to deter-
mine whether improvements in skeletal muscle function
are responsible for the improvements in endurance exer-
cise capacity and quality of life after pulmonary rehabilita-
tion. In addition, the methodology of exercise training
needs to be further studied. Some studies [26,61] have
shown that (for the same total work) exercise at high inten-
sity produces more benefits than exercise at lower levels
of intensity. These results differ from those obtained in
normal individuals. In normal persons, as long as the work
intensity is above a critical minimum intensity, it is the total
work performed and not the intensity of exercise that
determines the training response [62]. Whether the addi-
tion of strength training and/or upper limb training pro-
vides any additional benefits when added to lower limb
endurance training requires further study [63]. In one
study [64], the addition of strength training did not provide
any further benefits.
Oxygen therapy
Hypoxia reduces exercise performance in patients with
COPD. Possible mechanisms include reduced oxygen
delivery to the exercising muscle and increased ventilatory
requirements. Exercise performance improves in hypoxemic
patients with COPD when supplemental oxygen is adminis-
tered [65,66]. As described above, chronic hypoxia can
adversely affect skeletal muscle function. It has not yet
been determined whether the effects of chronic hypoxia
can be reversed by long-term oxygen therapy.
In one study [67] an increase in the creatine phosphate/
creatine phosphate + creatine ratio (measured from quadri-
ceps muscle biopsy) was observed after long-term oxygen
therapy in patients with COPD, suggesting a possible
improvement in skeletal muscle energy metabolism. The
same investigators did not observe any change in oxidative
enzyme activity after long-term oxygen therapy [15]. During
exercise, acute administration of supplemental oxygen to
hypoxemic patients with COPD improved aerobic metabo-
lism, as measured using MRS [24,68]. Long-term oxygen
therapy could also help by allowing patients to be more
active, thereby reducing the effects of deconditioning.
However, in one study [69] patients with COPD who
desaturated during exercise were randomized to receive
supplemental oxygen or air during exercise in the context of
a formal pulmonary rehabilitation program. Exercise perfor-
mance and quality of life improved in both groups, with no
significant differences between the groups.
Steroids
Because oral steroids have a deleterious effect on skeletal
muscle function, their use should be avoided whenever
possible. The efficacy of chronic oral steroid therapy in
stable patients with COPD is controversial at best. If
chronic oral therapy is contemplated, it should be clear
that simpler, less toxic therapeutic options have failed.
Chronic therapy should only be continued if a clear unam-
biguous response to a trial of therapy is observed. The
majority of patients will not show such a response [70]. In
contrast, administration of steroids during an acute exac-
erbation is beneficial [71]. Two weeks of therapy was just
as effective as 8 weeks of therapy, indicating that a pro-
longed taper of steroid dosage is not required. The long-
term effects of short bursts of high-dose steroids require
further study.
Nutrition
Because nutritional depletion has been associated with a
poorer outcome in patients with COPD [72,73], nutritional
repletion has been attempted. The results of this interven-
tion have not been encouraging. In a recent meta-analysis
[74], nutritional support had no significant effect on weight
gain, anthropometric measures, FEV1, respiratory muscle
strength, or 6-min walk distance. It was often difficult to
increase caloric intake substantially in outpatients with
COPD because many of the patients tended to decrease
their spontaneous intake of food in proportion to the
degree of supplementation. In one study [75], patients
were fed enterally via percutaneous gastrostomy. Caloric
intake was greater than two times the resting energy
expenditure. Patients gained weight, but the majority of
weight gained was fat and there was no significant
change in lean body mass. These results demonstrate that
nutritional support alone is not usually successful in
increasing lean body mass in patients with COPD.
Recent evidence [52,53] suggests that, in some nutrition-
ally depleted patients with COPD, weight loss may be
related to a systemic catabolic response induced by
inflammation. In such patients, it is believed that nutritional
support will not address the underlying problem, and
therefore will not be effective. In a relatively large study
[76], nutritional supplementation was administered while
patients underwent an inpatient pulmonary rehabilitation
program. Despite relatively modest nutritional supplemen-
tation, patients increased weight and, to a lesser extent,
Respiratory Research    Vol 2 No 4 Mador and Bozkanatfat-free mass as compared with a control group. Despite
the positive results for the group as a whole, many
patients did not gain weight with this approach. Unfortu-
nately, limb muscle strength and quality of life were not
measured. Inspiratory muscle strength was measured and
did not significantly improve in the nutritionally supported
group. Distance walked in 12 min improved in all groups
(all of the patients were undergoing an exercise training
program). There was no significant difference in the
degree of improvement between the patients who were
nutritionally supported and the control group who were
not. The combined effects of nutritional supplementation
and exercise training in nutritionally depleted patients with
COPD require further study.
Anabolic hormones
Anabolic hormones are important mediators of muscle
growth. Deficiencies in anabolic hormones lead to muscle
wasting. Because anabolic hormones can be exogenously
supplemented, this is an important area of research. Two
hormone systems that are known to effect muscle –
growth hormone and anabolic steroids – have been
studied in patients with COPD.
Growth hormone exerts its effects primarily by increasing
levels of insulin-like growth factors. In growth hormone-
deficient adults, administration of growth hormone
increases muscle mass and strength, and improves exer-
cise performance [77,78]. Administration of growth
hormone to healthy elderly individuals increases muscle
mass, but not muscle strength or endurance [79,80]. Two
controlled studies [81,82] examined whether administra-
tion of growth hormone would increase the benefits of
exercise training in patients with COPD. In both studies,
the group that received growth hormone plus exercise
training increased lean body mass, whereas the group that
received exercise training alone did not. In one study [82]
muscle cross-sectional area was measured, and increased
in the growth hormone group. Despite the increase in
muscle mass, no significant change in maximal inspiratory
muscle strength was observed [81,82]. The only measure
of peripheral muscle strength obtained was handgrip
strength, which did not change with exercise training in
either the growth hormone or control group [81]. There
were no significant differences between groups in the
improvements after training in peak exercise capacity,
whereas the improvements in endurance exercise were
not significantly different between groups in one study
[82], and were significantly less in the growth hormone
group in the other [81]. Growth hormone is extremely
expensive, and the data to date do not support its use in
patients with COPD.
In hypogonadal men, testosterone replacement increases
muscle mass and strength [83,84]. Although anabolic
steroids have been used by competitive athletes for years
to enhance performance, the effects of these agents in
eugonadal men remained controversial. Recently, it was
unambiguously shown [85] that anabolic steroids will
increase muscle size and strength in healthy eugonadal
men. Elderly men with mildly depressed testosterone
levels may respond to anabolic steroids by increasing
body weight and muscle strength [86].
Low testosterone levels are relatively common in patients
with COPD [87]. The effects of anabolic steroids in
patients with COPD with low testosterone levels have
not been evaluated. Two studies [76,88] evaluated the
effects of anabolic steroids in patients with COPD
undergoing pulmonary rehabilitation [76,88]. In one of
the studies the patients received nutritional supplemen-
tation in addition to anabolic steroids. In both studies,
there was a significant increase in weight and lean body
weight with anabolic steroids as compared with a control
group. Maximal inspiratory muscle strength increased
significantly in the anabolic steroid group in one study,
but not in the other. Measurements of limb muscle
strength were not performed. In the one study in which
these parameters were measured [88], peak exercise
capacity and 6-min walk distance were not significantly
improved in either the anabolic steroid or the control
group after pulmonary rehabilitation. Improvements in
peripheral muscle strength usually do not result in an
improvement in endurance exercise performance. When
strength training was added to an endurance exercise
program in patients with COPD the limb muscles did
become stronger, but this increase in strength did not
result in any additional improvement in exercise perfor-
mance or quality of life [64].
Conclusion
Skeletal muscle dysfunction is very common in patients
with COPD, and may play an important role in limiting
exercise performance in these patients. Muscle strength
and endurance are both decreased and the muscle is
more easily fatigued. Muscle atrophy is largely responsi-
ble for the reduction in muscle strength. Changes in fiber
type, reduced capillarity, decreased oxidative enzyme
capacity, and altered cellular bioenergetics have all been
documented in patients with COPD, and can potentially
explain the reduction in muscle endurance. Mechanisti-
cally, deconditioning is of major importance. Other
factors that are probably important in individual patients
include hypoxia or hypercapnia, nutritional depletion, and
steroid use. COPD may also produce a systemic inflam-
matory response that may adversely affect skeletal
muscle function, but more work is required to substanti-
ate this hypothesis. Exercise therapy has been shown to
improve skeletal muscle function. Other potential thera-
pies, such as oxygen supplementation, nutritional reple-
tion, and administration of anabolic steroids, require
further study.
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